Valuation: Asahi Kasei Corporation

Market Cap 2,115B 13.28B 12.05B 11.13B 10.04B 18.96B 1,240B 19.69B 134B 53.06B 669B 49.81B 48.76B P/E 2027 *
11.9x
P/E 2028 * 11.4x
Enterprise Value 2,784B 17.48B 15.87B 14.66B 13.22B 24.96B 1,633B 25.92B 177B 69.85B 881B 65.57B 64.19B EV / Sales 2027 *
0.83x
EV / Sales 2028 * 0.8x
Free-Float
95.42%
Yield 2027 *
2.9%
Yield 2028 * 3.26%
11-13 Asahi Kasei Homes Launches 12.88 Billion Yen Tender Offer for Mori-Gumi MT
11-12 Asahi Kasei, Circularise, And Furuya Metal Launch Demonstration Project For Precious Metal Traceability In Chlor-Alkali Electrolysis Electrodes CI
11-05 Asahi Kasei Posts Higher Fiscal H1 Attributable Income; Revenue Up MT
11-05 Asahi Kasei Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
11-05 Asahi Kasei Corporation Announces Dividend for the Second Quarter End of Fiscal Year Ending March 31, 2027, Payable on December 1, 2026; Revises Dividend Guidance for the Full Fiscal Year Ending March 31, 2027 CI
11-05 Asahi Kasei Corporation Reports Earnings Results for the Half Year Ended September 30, 2026 CI
11-04 Asahi Kasei Signs Memorandum of Understanding with Power to Hydrogen to Accelerate Commercialization of Anion Exchange Membrane Water Electrolysis for Clean Hydrogen Production CI
10-23 Asahi Kasei Pins Its Growth on Electronic Materials Zonebourse
10-10 Asahi Kasei Therapeutics, Inc. Announces FDA Approval Of HOVILPRI Tablets Developed By AiCuris Anti-Infective Cures AG For Mucocutaneous HSV Lesions Refractory To Standard Antiviral Treatment In Immunocompromised Adults CI
10-10 US FDA approves Asahi Kasei's drug for persistent herpes infections RE
10-09 Japan's Nikkei limps to weekly loss as AI doubts, bond stress weigh RE
10-08 Asahi Kasei Therapeutics Announces First Patient Dosed in Phase 2a Trial of AIC468 for BK Virus Infection in Kidney Transplant Recipients CI
10-01 Teijin Frontier, Asahi Kasei Advance Merge to Form TA Frontier MT
1 day-1.99%
1 week-2.78%
Current month-3.15%
1 month-3.36%
3 months-7.80%
6 months-8.05%
Current year+11.88%
1 week 1,539.5
Extreme 1539.50000000
1,650
1 month 1,474
Extreme 1474
1,660
Current year 1,415
Extreme 1415
1,906
1 year 1,247
Extreme 1247
1,906
3 years 880
Extreme 880
1,906
5 years 880
Extreme 880
1,906
10 years 606.1
Extreme 606.1
1,906
Manager TitleAgeSince
Director of Finance/CFO - -
President 67 01/04/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 71 01/04/2022
Director/Board Member 79 01/06/2018
Director/Board Member 67 01/06/2021
Change 5-day change 1-year change 3-year change Capi.($)
-1.99%-2.78%+23.92%+54.32% 13.28B
-0.70%-3.05%+23.55%+7.27% 63.54B
-1.14%-5.21%+23.25%+16.82% 49.54B
-0.29%-2.81%+2.63%+23.23% 16.73B
+0.38%-2.15%+22.58%-24.22% 9.21B
-7.76%-0.29%+77.24%-1.12% 8.34B
+0.92%-3.02%+25.54%+8.93% 8.81B
+0.51%-2.12%+15.93% - 8.75B
-1.78%-2.64%-13.33%+4.81% 7.88B
+1.32%-3.68%+32.88%+20.66% 5.58B
Average -1.03%-0.05%+23.42%+12.30% 19B
Weighted average by Cap. -0.97%+0.93%+22.46%+13.14%

Financials

2027 *2028 *
Net sales 3,370B 21.16B 19.21B 17.74B 16.01B 30.22B 1,977B 31.37B 214B 84.55B 1,067B 79.37B 77.7B 3,407B 21.39B 19.42B 17.93B 16.18B 30.55B 1,998B 31.71B 216B 85.48B 1,078B 80.24B 78.55B
Net income 179B 1.12B 1.02B 941M 849M 1.6B 105B 1.66B 11.34B 4.48B 56.57B 4.21B 4.12B 186B 1.17B 1.06B 978M 883M 1.67B 109B 1.73B 11.79B 4.66B 58.82B 4.38B 4.28B
Net Debt 669B 4.2B 3.81B 3.52B 3.18B 6B 392B 6.23B 42.45B 16.79B 212B 15.76B 15.43B 619B 3.88B 3.52B 3.26B 2.94B 5.55B 363B 5.76B 39.24B 15.52B 196B 14.57B 14.26B
Projected Income Statement - Annual - Asahi Kasei Corporation
Logo Asahi Kasei Corporation
Asahi Kasei Corp is a Japan-based company mainly engaged in the materials business, housing business and healthcare business. The Company operates through three business segments. The Materials segment provides styrene monomer, acrylonitrile, polyethylene, automotive-related fibers, electronic materials, mixed signal large scale integrated circuits (LSI), hall elements, deep ultraviolet light-emitting diodes (LEDs), pharmaceutical and food additives and others. The Housing segment provides construction contracting, renovation and other housing-related business, as well as lightweight aerated concrete (ALC), insulation materials and others. The Healthcare segment provides medical drugs, hemodialysis and apheresis related equipment, virus removal filters, cardiopulmonary resuscitation-related products and others. The Company also provides plant engineering, environmental engineering, various research and information provision businesses, and personnel dispatch and introduction services.
Employees
47,895
Date Price Change Volume
18/11/26 JP¥1,554.00 -1.99% 4,662,300
17/11/26 JP¥1,585.50 -1.28% 3,467,100
16/11/26 JP¥1,606.00 -1.50% 3,017,700
13/11/26 JP¥1,630.50 0.00% 3,180,300
12/11/26 JP¥1,630.50 +2.00% 4,031,300
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Asahi Kasei Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
1,585.50JPY
Average target price
1,948.18JPY
Spread / Average Target
+22.87%
  1. Stock Market
  2. Stocks
  3. 3407 Stock